Special Issue

Antibiotic Therapy Optimization in Special Populations

Message from the Guest Editors

Individualized precision antibiotic therapy is critical to optimize treatment outcomes because sufficient antimicrobial concentrations are imperative to achieve maximal killing activity. However, the design of optimal individualized antibiotic therapy regimen is particularly complicating for the patient populations whose gradual or acute pathophysiologic alterations substantially impact antimicrobial pharmacokinetics and pharmacodynamics. These patient populations are collectively called special populations and include critically ill patients, elderly populations, obese individuals, etc. In this Special Issue, scientific advances in designing optimal antibiotic therapy considering various patient characteristics will be discussed focusing on the aforementioned special patient populations. The multidisciplinary efforts in the field of antibiotic pharmacotherapy will provide insight for clinician scientists and healthcare professionals regarding the optimal antimicrobial therapy for special patient populations. Keywords: clinical pharmacometrics; PK/PD optimization of antibiotic therapy; special populations

Guest Editors

Dr. Eun Kyoung Chung

Division of Clinical Pharmacy/Infectious Diseases Pharmacotherapy, Department of Pharmacy, College of Pharmacy, Kyung Hee University, Seoul, Korea

Prof. Dr. Sara K. Quinney

Department of Obstetrics and Gynecology and Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA

Deadline for manuscript submissions

closed (30 September 2022)



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/93653

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

